PE20050477A1 - Terapia de combinacion para la infeccion de hcv - Google Patents

Terapia de combinacion para la infeccion de hcv

Info

Publication number
PE20050477A1
PE20050477A1 PE2004000979A PE2004000979A PE20050477A1 PE 20050477 A1 PE20050477 A1 PE 20050477A1 PE 2004000979 A PE2004000979 A PE 2004000979A PE 2004000979 A PE2004000979 A PE 2004000979A PE 20050477 A1 PE20050477 A1 PE 20050477A1
Authority
PE
Peru
Prior art keywords
hcv infection
combination therapy
combinations
referred
ribavirin
Prior art date
Application number
PE2004000979A
Other languages
English (en)
Inventor
Ene Ette
John J Alam
Robert Stephen Kauffman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE20050477A1 publication Critical patent/PE20050477A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A COMBINACIONES TERAPEUTICAS QUE COMPRENDEN VX-497, RIBAVIRINA E INTERFERON. DICHAS COMBINACIONES SON UTILES EN EL TRATAMIENTO DE LA INFECCION DE HCV O REDUCCION DE UNO O MAS SINTOMAS DE LA MISMA. TAMBIEN REFERIDA A KITS QUE COMPRENDEN ESTAS COMBINACIONES
PE2004000979A 2003-10-11 2004-10-11 Terapia de combinacion para la infeccion de hcv PE20050477A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11

Publications (1)

Publication Number Publication Date
PE20050477A1 true PE20050477A1 (es) 2005-08-24

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000979A PE20050477A1 (es) 2003-10-11 2004-10-11 Terapia de combinacion para la infeccion de hcv

Country Status (17)

Country Link
US (1) US20050112093A1 (es)
EP (1) EP1670462A1 (es)
JP (1) JP2007508326A (es)
KR (1) KR20060120037A (es)
CN (1) CN1882335A (es)
AR (1) AR045870A1 (es)
AU (1) AU2004281747A1 (es)
BR (1) BRPI0415249A (es)
CA (1) CA2541857A1 (es)
IL (1) IL174864A0 (es)
MX (1) MXPA06004077A (es)
NO (1) NO20062104L (es)
PE (1) PE20050477A1 (es)
RU (1) RU2006115916A (es)
TW (1) TW200528104A (es)
WO (1) WO2005037274A1 (es)
ZA (1) ZA200602912B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04023B1 (et) 1996-10-18 2003-04-15 Vertex Pharmaceuticals Incorporated Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
TW201424733A (zh) * 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
EP2402331A1 (en) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2646229A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
CN101903392A (zh) * 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
EA019965B1 (ru) * 2008-09-17 2014-07-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
EP2450051A4 (en) * 2009-06-30 2012-12-19 Meiji Seika Pharma Co Ltd MEDICAL AGENT AND METHOD FOR THE TREATMENT OF HARD-ANGLE CHRONIC HEPATITIS C
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
WO2018169283A1 (ko) * 2017-03-14 2018-09-20 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1116288C (zh) * 1996-04-23 2003-07-30 沃泰克斯药物股份有限公司 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
EP1213029A1 (en) * 1998-05-15 2002-06-12 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
US20040034206A1 (en) * 2002-05-31 2004-02-19 Schering Corporation Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors

Also Published As

Publication number Publication date
EP1670462A1 (en) 2006-06-21
TW200528104A (en) 2005-09-01
NO20062104L (no) 2006-05-10
CN1882335A (zh) 2006-12-20
WO2005037274A1 (en) 2005-04-28
AU2004281747A1 (en) 2005-04-28
BRPI0415249A (pt) 2006-12-12
CA2541857A1 (en) 2005-04-28
IL174864A0 (en) 2008-04-13
AR045870A1 (es) 2005-11-16
MXPA06004077A (es) 2006-06-27
ZA200602912B (en) 2007-06-27
US20050112093A1 (en) 2005-05-26
KR20060120037A (ko) 2006-11-24
JP2007508326A (ja) 2007-04-05
RU2006115916A (ru) 2007-12-10

Similar Documents

Publication Publication Date Title
PE20050477A1 (es) Terapia de combinacion para la infeccion de hcv
ATE461217T1 (de) Glp-1-verbindungen
ECSP055608A (es) Metodos de diagnostico y tratamiento de la pre-eclampsia o eclampsia
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
UY28258A1 (es) Tratamiento terapeutico
UA103496C2 (uk) Комбінація інгібітора протеази ns3 hcv з інтерфероном і рибавірином
UY27720A1 (es) Aroilpiridinonas monocíclicas,
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DOP2006000052A (es) Alargar el tiempo hasta la progresión de la enfermedad o la supervivencia de los pacientes de cáncer
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ECSP055823A (es) DERIVADOS DE [6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-SULFONILAMINO]-PROPIONAMIDA
ATE448232T1 (de) Substituierte heterozyklen
NO20052362D0 (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
MXPA04006572A (es) Terapia de combinacion antivirica.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
NO20054668L (no) Aplidin for multippelt myelom-behandling
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
IS7825A (is) Meðferðarfræðileg meðhöndlun
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
ECSP077423A (es) Coadministración de tigeciclina y digoxin
MXPA05011830A (es) Peptidos para uso en el tratamiento de la obesidad.
UY27827A1 (es) Composiciones y su uso terapeutico

Legal Events

Date Code Title Description
FC Refusal